Global Oral Antiviral Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Drug Class (Protease Inhibitors (PIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase

Global Oral Antiviral Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Drug Class (Protease Inhibitors (PIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors and Other Drug Classes), Indication, Distribution Channel, Region, By Country: 2020-2030

Background

A report published by Azoth Analytics highlights different factors and opportunities prevailing in the “Global Oral Antiviral Market (2024 Edition)”. According to the report, Global Oral Antiviral Market valued at USD 37.3 Billion in 2023 is expected to grow at a CAGR of 3.6% during 2025-2030.

The report explores a multi-faceted opportunity landscape in terms of market segmentation by Drug Class (Protease Inhibitors (PIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors and Other Drug Classes), By Indication (Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Other Indications) and By Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies)

Market Overview

The Oral Antiviral market has witnessed significant growth in recent years, driven by the increasing prevalence of viral infections, advancements in antiviral drug development, and the rising demand for effective oral treatments. Oral antivirals are medications administered orally to treat viral infections such as influenza, hepatitis, HIV, and COVID-19. The market's expansion is primarily fueled by the need for convenient and effective antiviral therapies that improve patient compliance and outcomes.

One of the primary drivers of the Oral Antiviral market is the increasing prevalence of viral infections worldwide. The global burden of viral diseases such as influenza, hepatitis, and HIV has led to a greater demand for effective antiviral treatments. Additionally, the COVID-19 pandemic has highlighted the critical need for antiviral therapies, further driving market growth.

Technological advancements have significantly impacted the Oral Antiviral market, leading to the development of innovative and potent antiviral drugs. Advances in drug discovery, formulation technologies, and delivery systems have resulted in oral antivirals that offer improved efficacy, safety, and patient adherence. These advancements are crucial for addressing the evolving challenges of viral infections and improving treatment outcomes.

The growing focus on pandemic preparedness and the need for effective treatments for emerging viral diseases have also played a crucial role in the market's expansion. Governments and healthcare organizations are investing in antiviral research and development to enhance their readiness for future pandemics and improve public health outcomes.

Sustainability trends are influencing the Oral Antiviral market as well. Pharmaceutical companies are increasingly focusing on developing environmentally friendly production processes and sustainable packaging solutions. This shift is driven by regulatory pressures and a growing awareness of environmental sustainability within the healthcare industry.

Segment Insights

By application, the hepatitis segment holds the largest market share, accounting for approximately 40% of the global Oral Antiviral market in 2023. Hepatitis B and C infections are prevalent worldwide, driving the demand for effective oral antiviral treatments in this segment.

Geographical Insights

Americas represent the largest market for Oral Antivirals in value terms, driven by the high prevalence of viral infections, advanced healthcare infrastructure, and significant investments in antiviral research and development. The United States, in particular, is a key market due to its strong focus on healthcare innovation and extensive use of antiviral therapies.

In the Americas, the market is further bolstered by favorable reimbursement policies, increasing healthcare expenditure, and a strong focus on pandemic preparedness. The presence of well-established healthcare facilities and a high level of awareness about viral diseases contribute to the market's dominance in this region.

The Asia Pacific region is expected to witness the highest growth rate due to the increasing prevalence of viral infections, growing healthcare expenditure, and rising investments in antiviral drug development. Countries like China, India, and Japan are at the forefront of this growth, with expanding healthcare infrastructure and a growing focus on improving public health.

Market Segmentation

By Drug Class:

• Protease Inhibitors (PIs)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Integrase Inhibitors
• Other Drug Classes

By Indication:

• Human Immunodeficiency Virus (HIV)
• Hepatitis
• Influenza
• Other Indications

By Distribution Channel:

• Hospital & Retail Pharmacies
• Online Pharmacies

By Geography

• Americas (The United States, Canada, Brazil, Mexico, Rest of Americas)
• Europe (United Kingdom, Germany, France, Italy, Spain, Turkey, Russia, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Singapore, Indonesia, Rest of Asia Pacific)
• Middle East and Africa (GCC, Israel, South Africa, Rest of Middle East and Africa)

Key Companies

The report assesses the competitive developments, strategies, mergers and acquisitions and new product development and market share portfolio of top 15 companies. Key companies in the Global Oral Antiviral Market include:

• AbbVie Inc.
• Johnson & Johnson
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• F. Hoffman-La Roche Ltd.
• Merck & Co., Inc.
• Viatris Inc.
• Amneal Pharmaceuticals LLC
• Gilead Sciences, Inc.
• Other Leading Companies

Reasons to buy this report:

• In-Depth Comparative Assessment of Top 20 Markets in the Oral Antiviral Industry: Comparative assessment of 20 leading countries highlighting the total addressable market, opportunities, lucrative segments and competitive positioning of leading companies.
• Comprehensive Historical, Present, and Future Analytics of the Oral Antiviral Market: A deep dive in the historical (2020-2023), current (2024) and forecast (2025-2030) market analytics of Oral Antiviral Market.
• Detailed Analysis of Oral Antiviral Market By Drug Class, Indication, and Distribution Channel Across 20 Countries
• Beyond the Purchase: 90 Days of Support
• Direct Access to Analysts: Have questions after reading the report? Our expert analysts are just a call or email away.
• Customized Assistance: Whether you're integrating insights into your strategy or have questions about market dynamics, our team provides tailored support to meet your specific business needs.
• Data Customization Requests: During the support period, you have the flexibility to request additional data cuts or deeper dives into specific areas of interest.
• Gain insights specific to new entrants or new market areas to tap: The study provides detailed market entry strategies, including analysis of barriers to entry, pricing strategies, opportunities, trends, drivers, and challenges and product positioning using the Opportunity Portfolio Matrix (OPM)
• Strategic Industry Movements: Tracking Competitive Developments and Key Players in the Market: The report covers competitive strategies, mergers & acquisitions, new developments, future plans and market share analysis of ~15 top companies

*Please Note: The report will be delivered in 2 business days upon order confirmation*